CLOSED
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Track Neuland Laboratories Limited's live NSE:NEULANDLAB share price ₹19,810.00 (+4.04%), market cap ₹₹254B, P/E 69.8. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for NEULANDLAB — real-time NSE India stock intelligence.
Open
₹19,149.00
High
₹19,912.00
Low
₹19,005.00
Prev. Close
₹19,040.00
52W High
₹20,089.00
52W Low
₹11,500.00
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Key Takeaway
Neuland Laboratories Limited is rated strong buy with a P/E of 69.8x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Neuland Laboratories Limited fairly valued right now?
Because a P/E of 69.8x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Neuland Laboratories Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
776 Cr
Revenue
213 Cr
Net Profit
0%
ROE
0%
ROCE
283.74
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 1,161 | 1,516 | 1,434 | 1,932 | 2,023 |
| Net Profit | 164 | 300 | 260 | 364 | 365 |
| ROE (%) | — | — | — | 0.0% | 0.0% |
| EPS (₹) | — | — | — | 283.74 | 283.74 |
| Debt/Equity | — | — | — | 16.1 | 16.1 |